SummitTX Capital L.P. lowered its holdings in Immunome, Inc. (NASDAQ:IMNM – Free Report) by 27.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 92,880 shares of the company’s stock after selling 34,733 shares during the quarter. SummitTX Capital L.P.’s holdings in Immunome were worth $2,031,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its stake in shares of Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA lifted its position in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Immunome during the 4th quarter worth about $30,710,000. Finally, Sofinnova Investments Inc. grew its holdings in Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after acquiring an additional 1,182,426 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.
Immunome Trading Up 2.8%
NASDAQ IMNM opened at $23.22 on Wednesday. The company has a market capitalization of $2.63 billion, a PE ratio of -9.76 and a beta of 2.07. The stock has a 50-day simple moving average of $21.15 and a 200 day simple moving average of $22.00. Immunome, Inc. has a 12 month low of $8.66 and a 12 month high of $27.65.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on IMNM. Truist Financial boosted their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.
View Our Latest Report on Immunome
Insider Activity at Immunome
In other Immunome news, Director Jean Jacques Bienaime acquired 10,500 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were acquired at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the acquisition, the director directly owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. This trade represents a 31.90% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the transaction, the chief financial officer directly owned 54,037 shares in the company, valued at approximately $985,094.51. The trade was a 52.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 472,142 shares of company stock valued at $10,262,648 over the last 90 days. Insiders own 7.21% of the company’s stock.
Immunome Profile
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
- Five stocks we like better than Immunome
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report).
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
